News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1SanDisk (SNDK) FY2026 Q3 Earnings Highlights: 97% QoQ Revenue Surge, Q4 Guidance Raised Again!2Apple FY2026 Q2 Earnings Highlights: Record Revenue and EPS, Q3 Guidance Tops Expectations3Eli Lilly (LLY) Q1 2026 Earnings Highlights: GLP-1 Momentum Fuels Strong Beat, Guidance Raised
BR (Bedrock) 24-hour volatility at 57.7%: Trading volume surges over 5 times, causing sharp price fluctuations
Bitget Pulse·2026/05/01 16:02
AIAV (AIAvatar) 24-hour amplitude reaches 107.9%: Low liquidity trading amplifies price volatility
Bitget Pulse·2026/05/01 16:02
TAC (TAC) fluctuates 46.3% within 24 hours: Trading volume soars, triggering speculative rebound
Bitget Pulse·2026/05/01 16:02
USD/JPY steadies after Japan’s intervention checks Yen slide
FXStreet·2026/05/01 15:57
GBP/USD surges past 1.3600 as Yen intervention batters Dollar
FXStreet·2026/05/01 15:45
Dogecoin Hits 2-Month High as DOGE Mining Firm Plans to Go Public via Merger
Decrypt·2026/05/01 15:03
Flash
16:04
Fulton Financial has filed documents with the U.S. Securities and Exchange Commission seeking to issue a tranche of fixed-to-floating rate subordinated notes due in 2036.According to the filing documents, the specific size of this issuance has not yet been disclosed.
16:04
The U.S. Food and Drug Administration (FDA) has issued a "safe to proceed" letter to Revolution Medicines, Inc., approving the initiation of an expanded access program for its investigational drug Daraxonrasib for the treatment of pancreatic cancer patients.Obtaining this letter means that Revolution Medicines can begin providing this experimental treatment to eligible pancreatic cancer patients. The expanded access program aims to make promising investigational therapies available to patients who have not yet participated in clinical trials. Daraxonrasib is a targeted therapy drug developed by Revolution Medicines, and the approval of this expanded access program will offer new treatment options for pancreatic cancer patients. This development marks an important step forward in the clinical development of this medication.
16:04
CBOE Global Markets Inc recently disclosed that its restructuring expenses will mainly be recognized during the second to fourth quarter of 2026.This timeframe indicates that the key financial impacts of the company's structural adjustments will be concentrated within this period.
News